News
CELC
95.93
-0.47%
-0.45
10 mid-cap U.S. healthcare stocks with the strongest momentum grades
Seeking Alpha · 1d ago
Weekly Report: what happened at CELC last week (0615-0619)?
Weekly Report · 3d ago
Weekly Report: what happened at CELC last week (0608-0612)?
Weekly Report · 06/15 09:05
Celcuity Refinances Debt with New Convertible Notes Offering
TipRanks · 06/08 20:36
Weekly Report: what happened at CELC last week (0601-0605)?
Weekly Report · 06/08 09:05
BUZZ-U.S. STOCKS ON THE MOVE -Honeywell, Broadcom, Carlyle
Reuters · 06/04 17:48
BUZZ-U.S. STOCKS ON THE MOVE-UnitedHealth,  Pinterest, Celcuity
Reuters · 06/04 15:47
BUZZ-Celcuity rises after boosted $500 mln convertible bond offering
Reuters · 06/04 14:25
Celcuity prices $500M convertible senior note offering
TipRanks · 06/04 11:42
Celcuity raises $500M in upsized 0.25% convertible notes sale
Seeking Alpha · 06/04 09:56
Celcuity Prices $480 Mln Upsized Public Offering In Convertible Senior Notes
NASDAQ · 06/04 08:42
Reported Earlier, Celcuity Prices Upsized $500M Convertible Notes Offering (Up From Prior $400M)
Benzinga · 06/04 08:14
CELCUITY - PRICES UPSIZED $500 MLN 0.25% CONVERTIBLE SENIOR NOTES DUE 2032
Reuters · 06/04 02:13
Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
Barchart · 06/03 21:13
Celcuity Price Target Cut to $171.00/Share From $189.00 by Craig-Hallum
Dow Jones · 06/03 17:47
Celcuity Is Maintained at Buy by Craig-Hallum
Dow Jones · 06/03 17:47
BUZZ-U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
Reuters · 06/03 17:44
Craig-Hallum Maintains Buy on Celcuity, Lowers Price Target to $171
Benzinga · 06/03 17:37
BUZZ-U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway
Reuters · 06/03 15:42
Celcuity price target lowered to $171 from $189 at Craig-Hallum
TipRanks · 06/03 15:14
More
Webull provides a variety of real-time CELC stock news. You can receive the latest news about Celcuity Inc through multiple platforms. This information may help you make smarter investment decisions.
About CELC
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a kinase inhibitor of phosphatidylinositol 3-kinase (PI3K), serine/threonine-protein kinase protein kinase B (AKT), mechanistic target of rapamycin (mTOR) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and mTORC2. A Phase III clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) (HR+/HER2-) advanced breast cancer (ABC) has completed enrollment and reported detailed results for cohort 1, patients with PIK3CA wild-type (WT) tumors, and has completed enrollment of cohort 2, patients with PIK3CA mutant-type (MT) tumors.